Status:
UNKNOWN
Liver Transplantation in Patients With Incidental Hepatocellular-cholangiocarcinoma and Intrahepatic Cholangiocarcinoma: A Single-center Experience
Lead Sponsor:
Istanbul Demiroglu Bilim University
Conditions:
Adult Combined Hepatocellular-Cholangiocarcinoma
Eligibility:
All Genders
18-78 years
Brief Summary
Liver transplantation has become an important treatment in hepatocellular cancer (HCC). While the generally determined malign indication in the world is HCC, some centers perform liver transplantation...
Detailed Description
Combined hepatocellular and cholangiocarcinoma (CHC) with an incidence rate from 0.4% to 14.2% in different regions, characterized by hepatocellular and biliary epithelial differentiation within the s...
Eligibility Criteria
Inclusion
- Explant pathology Being Combined Hepatocellular-Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma
- Having a liver transplant
- Being over 18 years old
Exclusion
- Explant pathology being hepatocellular carcinoma
- Being under the age of 18
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
279 Patients enrolled
Trial Details
Trial ID
NCT04848805
Start Date
March 1 2020
End Date
May 1 2022
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Group Florence Nightingale Hospitals
Istanbul, Turkey (Türkiye), 34349